Alan Russell

This inventor holds 12 USPTO granted patents and 5 published patent applications and 5 EPO patents. Top assignees: Edgewise Therapeutics, Inc., Edgewise Therapecutics, Inc., Servier Pharmaceuticals LLC. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan Russell. Retrieved from https://idiyas.com/inventor/alan-russell-payk33zh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 5)

% Patents Active = 91.7

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 32(Granted Patents)

Company Filing History:

9 out of 9

Edgewise Therapeutics, Inc.

patents

2 out of 2

Edgewise Therapecutics, Inc.

patents

1 out of 24

Servier Pharmaceuticals LLC

patents

Years Active: 2021-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758551 - Substituted pyridazinones for use in the treatment of neuromuscular diseases (2026-10-13),

2. 12643892 - Pyridazinone compounds for the treatment of neuromuscular diseases (2026-06-02),

3. 12559464 - Quinazolinone dione compounds and uses thereof (2026-02-24),

4. 12509431 - 1,4-dihydroquinazolinone compounds and uses thereof (2025-12-30),

5. 12448369 - Quinolinone amide compounds and uses thereof (2025-10-21),

6. 12415794 - Pyridazinone compounds and uses thereof (2025-09-16),

7. 12240833 - Pyridazinone compounds and uses thereof (2025-03-04),

8. 12240831 - Pyridazinone compounds and uses thereof (2025-03-04),

9. 12012395 - Pyridazinone compounds and uses thereof (2024-06-18),

10. 11390606 - Pyridazinone compounds and uses thereof (2022-07-19),

11. 11236065 - Pyridazinone compounds and uses thereof (2022-02-01),

12. 11091464 - Pyridazinone compounds and uses thereof (2021-08-17),

Title: Alan Russell: Innovator in Pharmaceutical Compounds

Introduction

Alan Russell is a prominent inventor based in Boulder, CO (US), known for his significant contributions to the field of pharmaceutical compounds. With a total of 12 patents, he has made strides in developing innovative treatments for various medical conditions.

Latest Patents

Among his latest patents, Russell has developed quinolinone amide compounds and their uses. This patent focuses on substituted quinolinone amide compounds or salts that may be utilized to treat or prevent cardiac disease in individuals in need. Another notable patent involves pyridazinone compounds, which are designed for the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD). These compounds are particularly useful in modulating inflammatory inhibitors like IL-1, IL-6, or TNF-α.

Career Highlights

Throughout his career, Alan Russell has worked with notable companies, including Edgewise Therapeutics, Inc. and Edgewise Therapeutics, Inc. His work has been instrumental in advancing pharmaceutical research and development.

Collaborations

Russell has collaborated with esteemed colleagues, including Kevin W. Hunt and Kevin Koch, contributing to the innovative environment in which he operates.

Conclusion

Alan Russell's work in developing pharmaceutical compounds showcases his dedication to improving healthcare through innovation. His patents reflect a commitment to addressing critical medical challenges, particularly in cardiac and neuromuscular diseases.

Profile summary based on public USPTO records.